SIGA Technologies/$SIGA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SIGA Technologies
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Ticker
$SIGA
Sector
Primary listing
Employees
46
Headquarters
Website
SIGA Metrics
BasicAdvanced
$644M
7.90
$1.14
0.95
$0.60
6.67%
Price and volume
Market cap
$644M
Beta
0.95
52-week high
$9.62
52-week low
$4.95
Average daily volume
631K
Dividend rate
$0.60
Financial strength
Current ratio
10.089
Quick ratio
8.317
Long term debt to equity
0.237
Total debt to equity
0.51
Profitability
EBITDA (TTM)
101.586
Gross margin (TTM)
69.00%
Net profit margin (TTM)
45.75%
Operating margin (TTM)
56.25%
Effective tax rate (TTM)
23.31%
Revenue per employee (TTM)
$3,910,000
Management effectiveness
Return on assets (TTM)
29.51%
Return on equity (TTM)
43.61%
Valuation
Price to earnings (TTM)
7.899
Price to revenue (TTM)
3.578
Price to book
3.08
Price to tangible book (TTM)
3.09
Price to free cash flow (TTM)
5.401
Free cash flow yield (TTM)
18.52%
Free cash flow per share (TTM)
1.666
Dividend yield (TTM)
6.67%
Growth
Revenue change (TTM)
3.86%
Earnings per share change (TTM)
-2.56%
3-year revenue growth (CAGR)
6.81%
10-year revenue growth (CAGR)
44.27%
3-year earnings per share growth (CAGR)
5.44%
10-year earnings per share growth (CAGR)
-13.92%
What the Analysts think about SIGA
Analyst ratings (Buy, Hold, Sell) for SIGA Technologies stock.
Bulls say / Bears say
SIGA Technologies reported $79.1 million in product revenues for Q2 2025, a 282% increase from $20.7 million the year before, driven by $53 million in oral and $26 million in IV TPOXX deliveries to the Strategic National Stockpile.
In Q2 2025, SIGA received an additional $27 million in development funding under the BARDA 19C contract, including $13 million for its pediatric TPOXX program and $14 million for manufacturing support, indicating continued government investment.
On January 2, 2025, SIGA’s TEPOXX (tecovirimat) became the first antiviral approved by Japan’s PMDA for orthopoxviruses, increasing the company’s addressable market and marking its initial commercial presence in Asia.
SIGA’s Q2 2025 revenues were entirely dependent on U.S. government stockpile orders, highlighting the company’s lack of commercial diversification outside government contracts.
The company’s dependence on a single product, TPOXX, under the BARDA 19C contract means that changes or non-renewals to this contract could have a significant negative impact on future revenues.
As of June 30, 2025, roughly $26 million in U.S. government orders were outstanding and are not expected to be delivered until 2026, which may lead to gaps in revenue recognition toward the end of 2025.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
SIGA Financial Performance
Revenues and expenses
SIGA Earnings Performance
Company profitability
SIGA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SIGA Technologies stock?
SIGA Technologies (SIGA) has a market cap of $644M as of September 16, 2025.
What is the P/E ratio for SIGA Technologies stock?
The price to earnings (P/E) ratio for SIGA Technologies (SIGA) stock is 7.9 as of September 16, 2025.
Does SIGA Technologies stock pay dividends?
Yes, the SIGA Technologies (SIGA) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $0.6 and the yield is 6.67%. SIGA Technologies has a payout ratio of 0% on a trailing twelve-month basis.
When is the next SIGA Technologies dividend payment date?
The next SIGA Technologies (SIGA) dividend payment date is unconfirmed.
What is the beta indicator for SIGA Technologies?
SIGA Technologies (SIGA) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.